- Home
- SEER vs ATOS Comparison
SEER vs ATOS Comparison
Compare SEER & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEER
- ATOS
- Stock Information
- Founded
- SEER 2017
- ATOS 2009
- Country
- SEER United States
- ATOS United States
- Employees
- SEER 134
- ATOS N/A
- Industry
- SEER Medicinal Chemicals and Botanical Products
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- SEER Health Care
- ATOS Health Care
- Exchange
- SEER Nasdaq
- ATOS Nasdaq
- Market Cap
- SEER 115.5M
- ATOS 107.2M
- IPO Year
- SEER 2020
- ATOS 2012
- Fundamental
- Price
- SEER $2.11
- ATOS $0.78
- Analyst Decision
- SEER
- ATOS Strong Buy
- Analyst Count
- SEER 0
- ATOS 3
- Target Price
- SEER N/A
- ATOS $6.17
- AVG Volume (30 Days)
- SEER 134.2K
- ATOS 1.3M
- Earning Date
- SEER 08-06-2025
- ATOS 08-12-2025
- Dividend Yield
- SEER N/A
- ATOS N/A
- EPS Growth
- SEER N/A
- ATOS N/A
- EPS
- SEER N/A
- ATOS N/A
- Revenue
- SEER $16,288,000.00
- ATOS N/A
- Revenue This Year
- SEER $27.05
- ATOS N/A
- Revenue Next Year
- SEER $28.33
- ATOS N/A
- P/E Ratio
- SEER N/A
- ATOS N/A
- Revenue Growth
- SEER 10.52
- ATOS N/A
- 52 Week Low
- SEER $1.59
- ATOS $0.55
- 52 Week High
- SEER $2.63
- ATOS $1.66
- Technical
- Relative Strength Index (RSI)
- SEER 49.69
- ATOS 45.59
- Support Level
- SEER $2.02
- ATOS $0.81
- Resistance Level
- SEER $2.10
- ATOS $0.80
- Average True Range (ATR)
- SEER 0.08
- ATOS 0.03
- MACD
- SEER -0.01
- ATOS -0.00
- Stochastic Oscillator
- SEER 42.42
- ATOS 39.58
About SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.